Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers

Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers

Abstract Background Mortalin is enriched in a large variety of cancers and has been shown to contribute to proliferation and migration of cancer cells in multiple ways. It has been shown to bind to p53 protein in cell cytoplasm and nucleus causing inactivation of its tumor suppressor activity in can...

Full description

Bibliographic Details
Main Authors: Jayarani F. Putri, Priyanshu Bhargava, Jaspreet Kaur Dhanjal, Tomoko Yaguchi, Durai Sundar, Sunil C. Kaul, Renu Wadhwa
Format: Article
Language:English
Published: BMC 2019-12-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Mortaparib
Mortalin
p53
PARP1
Inhibitor
Growth arrest
Online Access:https://doi.org/10.1186/s13046-019-1500-9

Similar Items

Similar Items